BASEL, Switzerland, 4 December 2007 - Nitec Pharma AG ("Nitec"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced that it has appointed Hans Fünfschilling as its new non-executive Chairman of the Board. Hans Fünfschilling succeeds Hubertus Ludwig who has been chairman since the foundation of Nitec. Hubertus Ludwig will continue to serve on the Board of the company.
